Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotechnology company. Pluristem uses placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. Pluristem�s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells are a cell therapy product defined as mesenchymal-like adherent stromal cells (ASCs) derived from full term human placentas. Pluristem manufactures placenta-based cell products using a 3D bioreactor. Pluristem is pursuing multiple indications including Cardiovascular, Orthopedic, Pulmonary and Hematological diseases as well as preeclampsia. Through Pluristem�s in-house manufacturing facility the Company produces homogeneous, clinical-grade cells.